Oncology
Glaxosmithkline Research & Development Limited funds clinical research across multiple cancer settings, including solid tumours, breast cancer, prostate cancer, lung cancer, colorectal cancer, head and neck cancer, ovarian cancer, and multiple myeloma. Its studies also include advanced and relapsed or refractory disease, with interest in both tumour-directed therapy and immunotherapy combinations.
- Advanced solid tumours
- Non-small cell lung cancer
- Relapsed or refractory multiple myeloma
- Metastatic breast and prostate cancer
Research also extends to biomarker-defined cancers such as dMMR/MSI-H colorectal cancer and PD-L1-positive tumours, reflecting a strong focus on precision oncology and combination treatment strategies.
Respiratory and airway disease
The sponsor has a major portfolio in asthma, including severe eosinophilic asthma, type 2 inflammation, and mild asthma, alongside studies in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. It also funds research in systemic sclerosis-associated interstitial lung disease and other connective tissue disease-associated interstitial lung diseases.
- Severe asthma with eosinophilic phenotype
- COPD and type 2 inflammation
- Idiopathic pulmonary fibrosis
- Interstitial lung disease linked to connective tissue disease
Additional work includes airway mucus and lung-function research in inflammatory respiratory disease, as well as paediatric and adult studies involving inhaled therapy and respiratory infection.
Immunology and autoimmune disease
Clinical research also targets systemic lupus erythematosus, systemic sclerosis, atopic dermatitis, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and related immune-mediated conditions. These studies span adult and paediatric populations and include both chronic inflammatory and rare immune disorders.
- Systemic lupus erythematosus
- Atopic dermatitis
- Hypereosinophilic syndrome
- Systemic sclerosis
There is also interest in connective tissue diseases and immune dysregulation affecting the lungs, skin, and blood, with studies addressing long-term disease control and symptom burden.
Viral and hepatobiliary disease
The sponsor funds research in chronic hepatitis B, including HBV/HIV coinfection, as well as studies in cholestatic pruritus, primary biliary cholangitis, non-alcoholic fatty liver disease, and alcohol-related liver disease. Its portfolio reflects sustained interest in liver-related inflammation, viral persistence, and cholestatic symptoms.
- Chronic hepatitis B
- HBV and HIV coinfection
- Primary biliary cholangitis
- Non-alcoholic fatty liver disease
It also includes antiviral research in influenza and studies involving tuberculosis, broadening its infectious disease activity beyond hepatology.
Neurology, nephrology, and pain
Glaxosmithkline Research & Development Limited supports clinical studies in early Alzheimer’s disease, autosomal dominant polycystic kidney disease, kidney disease, diabetic peripheral neuropathic pain, and knee osteoarthritis pain. These programmes cover neurodegenerative, renal, and chronic pain conditions across adult populations.
- Early Alzheimer’s disease
- Autosomal dominant polycystic kidney disease
- Diabetic peripheral neuropathic pain
- Knee osteoarthritis pain
Its research in this area also includes symptom-focused evaluation in chronic conditions such as pruritus and long-standing inflammatory disease.
